Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants [Phase 2]
A Phase 2 trial evaluating the safety, tolerability, and immune response of the Meningococcal Combined ABCWY Vaccine in healthy infants has …
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon [Phase 3]
Phase 3 trial assessing safety and immunogenicity of a single-dose MenACYW Conjugate Vaccine in older adults in Turkey and Lebanon has compl…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age [Phase 3]
Phase 3 trial results evaluating the safety and immunogenicity of the GSK Meningococcal Group B Vaccine when administered concurrently with …
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults [Phase 1, Phase 2]
This clinical trial update reports Phase 1/2 results assessing the safety, effectiveness, and immune response of the Meningococcal ABCWY vac…
-
EMA approval · 2025-02-13EMA Authorised: Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid) — Pfizer Europe MA EEIG
The EMA authorised Nimenrix, a quadrivalent meningococcal conjugate vaccine, for prevention of invasive meningococcal disease caused by sero…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-02-05EMA Withdrawn: Penbraya (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group B fHBP protein subfamily A;Neisseria meningitidis group B fHBP protein subfamily B) — Pfizer Europe MA EEIG
EMA has withdrawn the marketing authorization for Penbraya, a meningococcal vaccine developed by Pfizer Europe MA EEIG. The withdrawal took …
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa [Phase 3]
A Phase 3 trial evaluating the immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine in healthy adult…
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe [Phase 3]
A Phase 3 study evaluated the immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine when co-administered with routine …
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules [Phase 2]
This Phase 2 trial update describes safety and immunogenicity results for the MenABCWY meningococcal vaccine given on two dosing schedules.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age [Phase 4]
Phase 4 trial assessing safety, tolerability, and immunogenicity of Pfizer's meningococcal group B vaccine Trumenba (rLP2086) in immunocompr…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine given with routine pediatric vaccines i…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine [Phase 3]
Phase 3 immunogenicity and safety results for GSK's MenABCWY meningococcal vaccine in healthy adolescents and adults previously primed with …
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers [Phase 3]
Phase 3 study of an investigational MenACYW Conjugate Vaccine evaluating 5- and/or 10-year booster doses in children and adolescents who wer…
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months [Phase 3]
Phase 3 trial update assessing immunogenicity and safety of a meningococcal ACYW135 polysaccharide conjugate vaccine in infants aged 3 to 5 …
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months [Phase 3]
A Phase 3 trial update reports on the immunogenicity and safety of group A and C meningococcal polysaccharide conjugate vaccine in healthy i…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants [Phase 2]
Phase 2 trial assessing safety, tolerability, and immunogenicity of MenABCWY vaccine in healthy infants was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age [Phase 3]
A Phase 3 trial evaluating safety and immunogenicity of Nimenrix given at 3 and 12 months in healthy infants has completed with results post…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults [Phase 3]
Phase 3 trial update assessing the effectiveness of GlaxoSmithKline's meningococcal Group B and ABCWY vaccines in healthy adolescents and yo…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico [Phase 3]
Phase 3 trial assessing safety and immunogenicity of a quadrivalent meningococcal vaccine given with routine pediatric vaccines in healthy i…
-
FDA approval · 2023-08-16FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application to add an intravenous formulation of rifampin (RIFADIN IV).
-
FDA approval · 2023-08-16FDA Approved: RIFAMPIN — Supplemental Application (EPIC PHARMA, LLC)
FDA approved a supplemental application for Rifampin from Epic Pharma, LLC. The approval likely updates labeling or indications for the prod…
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. [Phase 3]
Phase 3 trial assessing immunogenicity and safety of two doses of bivalent rLP2086 (Trumenba) and a pentavalent meningococcal vaccine in hea…
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: A Sourcing Study to Collect Human Blood Samples From Healthy Adults [Phase 4]
Phase 4 trial update describing collection of human blood samples from healthy adults; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents [Phase 3]
Phase 3 trial comparing MenACYW Conjugate Vaccine to a meningococcal reference vaccine and evaluating administration alone or with two other…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age [Phase 3]
A Phase 3 noninferiority study evaluating MenABCWY vaccine in healthy adolescents and young adults completed with results posted in 2023.